ProCE Banner Activity

A Changing Treatment Paradigm of Myasthenia Gravis: A Focus on Novel Targeted Treatments

Slideset

This presentation will educate healthcare providers on the historical treatment of myasthenia gravis, how the newer agents change the treatment paradigm, and demonstrate how to treat various subtypes of myasthenia gravis through patient case examples.

Released: September 23, 2022

Expiration: September 22, 2023

No longer available for credit.

Share

Faculty

Jonathan Katz

Jonathan Katz, MD

Director
Department of Neurology
Forbes Norris MDA ALS Center
California Pacific Medical Center
San Francisco, California

Gil Wolfe

Gil Wolfe, MD, FAAN

Irving and Rosemary Smith Professor and Chairman, SUNY Distinguished Professor
Department of Neurology
University at Buffalo/SUNY Jacobs School of Medicine and Biomedical Services
Buffalo, New York

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

Independent Educational Activity

Faculty Disclosure

Primary Author

Jonathan Katz, MD

Director
Department of Neurology
Forbes Norris MDA ALS Center
California Pacific Medical Center
San Francisco, California

Jonathan Katz, MD: consultant/advisor/speaker: Alexion, Argenx, Biogen, Calico, Denali, Grifols, PTC Therapeutics, Takeda, Wave Life Sciences.

Gil Wolfe, MD, FAAN

Irving and Rosemary Smith Professor and Chairman, SUNY Distinguished Professor
Department of Neurology
University at Buffalo/SUNY Jacobs School of Medicine and Biomedical Services
Buffalo, New York

Gil Wolfe, MD, FAAN: consultant/advisor/speaker: Alexion, Argenx, Grifols, Janssen, Takeda, UCB; researcher: Roche, Sanofi.